eli lilly
Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies
Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration
Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound
Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma
Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline
Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
Eli Lilly Invests $5.3 Billion to Boost Production of Mounjaro and Zepbound
** Eli Lilly, Mounjaro, Zepbound, Manufacturing, Investment, Diabetes, Obesity, Weight Loss, Pharmaceutical Industry
Eli Lilly’s State Law Attempt to Halt Florida Compounding Pharmacy’s Tirzepatide Sales Dismissed
Eli Lilly, Florida compounding pharmacy, RXCompoundStore.com, Tirzepatide (Mounjaro/ Zepbound), Judge Roy Altman, Federal Food/ Drug/ and Cosmetic Act (FDCA), Frivolous lawsuits
FDA Unexpectedly Postpones Approval Decision for Eli Lilly’s Donanemab, Schedules AdComm Review
Donanemab, Eli Lilly, FDA delay, Approval postponement, Peripheral and Central Nervous System Drugs Advisory Committee (PCNS), Safety and efficacy review, Clinical trial results, Brain swelling and bleeding side effects, Accelerated approval declined, Leqembi and Aduhelm precedent, Full approval anticipated, Accelerated approval rejected.